MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin

E. Cecchin, G. Perrone, S. Nobili, J. Polesel, E. De Mattia, C. Zanusso, P. Petreni, S. Lonardi, N. Pella, M. D'Andrea, D. Errante, F. Rizzolio, T. Mazzei, I. Landini, E. Mini, G. Toffoli

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Adjuvant treatment based on fluoropyrimidines (FL) improves the prognosis of stage II/III colorectal cancer (CRC). Validated predictive/prognostic biomarkers would spare therapy-related morbidity in patients with a good prognosis. We compared the impact of a set of 22 FL-related polymorphisms with the prognosis of two cohorts of CRC patients treated with adjuvant FL with or without OXA, including a total of 262 cases. 5,10-Methylentetrahydrofolate reductase (MTHFR) MTHFR-1298 A>C (rs1801131) polymorphism had a concordant effect: MTHFR-rs1801131-1298CC genotype carriers had a worse disease free survival (DFS) in both the cohorts. In the pooled population MTHFR-rs1801131-1298CC carriers had also a worse overall survival. We computed a clinical score related to DFS including MTHFR-rs1801131, tumor stage, sex and tumor location, where rs1801131 is the most detrimental factor (hazard ratio=5.3, 95% confidence interval=2.2-12.9; P-value=0.0006). MTHFR-rs1801131 is a prognostic factor that could be used as an additional criteria for the choice of the proper adjuvant regimen in stage II/III colorectal cancer patients.

Original languageEnglish
Pages (from-to)219-225
Number of pages7
JournalPharmacogenomics Journal
Volume15
Issue number3
DOIs
Publication statusPublished - Jun 26 2015

Fingerprint

oxaliplatin
Adjuvant Chemotherapy
Colorectal Neoplasms
Oxidoreductases
Survival
Disease-Free Survival
Neoplasms
Biomarkers
Genotype

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics
  • Medicine(all)

Cite this

MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin. / Cecchin, E.; Perrone, G.; Nobili, S.; Polesel, J.; De Mattia, E.; Zanusso, C.; Petreni, P.; Lonardi, S.; Pella, N.; D'Andrea, M.; Errante, D.; Rizzolio, F.; Mazzei, T.; Landini, I.; Mini, E.; Toffoli, G.

In: Pharmacogenomics Journal, Vol. 15, No. 3, 26.06.2015, p. 219-225.

Research output: Contribution to journalArticle

Cecchin, E. ; Perrone, G. ; Nobili, S. ; Polesel, J. ; De Mattia, E. ; Zanusso, C. ; Petreni, P. ; Lonardi, S. ; Pella, N. ; D'Andrea, M. ; Errante, D. ; Rizzolio, F. ; Mazzei, T. ; Landini, I. ; Mini, E. ; Toffoli, G. / MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin. In: Pharmacogenomics Journal. 2015 ; Vol. 15, No. 3. pp. 219-225.
@article{8337011acc224a83b91a2d92692c17ad,
title = "MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin",
abstract = "Adjuvant treatment based on fluoropyrimidines (FL) improves the prognosis of stage II/III colorectal cancer (CRC). Validated predictive/prognostic biomarkers would spare therapy-related morbidity in patients with a good prognosis. We compared the impact of a set of 22 FL-related polymorphisms with the prognosis of two cohorts of CRC patients treated with adjuvant FL with or without OXA, including a total of 262 cases. 5,10-Methylentetrahydrofolate reductase (MTHFR) MTHFR-1298 A>C (rs1801131) polymorphism had a concordant effect: MTHFR-rs1801131-1298CC genotype carriers had a worse disease free survival (DFS) in both the cohorts. In the pooled population MTHFR-rs1801131-1298CC carriers had also a worse overall survival. We computed a clinical score related to DFS including MTHFR-rs1801131, tumor stage, sex and tumor location, where rs1801131 is the most detrimental factor (hazard ratio=5.3, 95{\%} confidence interval=2.2-12.9; P-value=0.0006). MTHFR-rs1801131 is a prognostic factor that could be used as an additional criteria for the choice of the proper adjuvant regimen in stage II/III colorectal cancer patients.",
author = "E. Cecchin and G. Perrone and S. Nobili and J. Polesel and {De Mattia}, E. and C. Zanusso and P. Petreni and S. Lonardi and N. Pella and M. D'Andrea and D. Errante and F. Rizzolio and T. Mazzei and I. Landini and E. Mini and G. Toffoli",
year = "2015",
month = "6",
day = "26",
doi = "10.1038/tpj.2014.64",
language = "English",
volume = "15",
pages = "219--225",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin

AU - Cecchin, E.

AU - Perrone, G.

AU - Nobili, S.

AU - Polesel, J.

AU - De Mattia, E.

AU - Zanusso, C.

AU - Petreni, P.

AU - Lonardi, S.

AU - Pella, N.

AU - D'Andrea, M.

AU - Errante, D.

AU - Rizzolio, F.

AU - Mazzei, T.

AU - Landini, I.

AU - Mini, E.

AU - Toffoli, G.

PY - 2015/6/26

Y1 - 2015/6/26

N2 - Adjuvant treatment based on fluoropyrimidines (FL) improves the prognosis of stage II/III colorectal cancer (CRC). Validated predictive/prognostic biomarkers would spare therapy-related morbidity in patients with a good prognosis. We compared the impact of a set of 22 FL-related polymorphisms with the prognosis of two cohorts of CRC patients treated with adjuvant FL with or without OXA, including a total of 262 cases. 5,10-Methylentetrahydrofolate reductase (MTHFR) MTHFR-1298 A>C (rs1801131) polymorphism had a concordant effect: MTHFR-rs1801131-1298CC genotype carriers had a worse disease free survival (DFS) in both the cohorts. In the pooled population MTHFR-rs1801131-1298CC carriers had also a worse overall survival. We computed a clinical score related to DFS including MTHFR-rs1801131, tumor stage, sex and tumor location, where rs1801131 is the most detrimental factor (hazard ratio=5.3, 95% confidence interval=2.2-12.9; P-value=0.0006). MTHFR-rs1801131 is a prognostic factor that could be used as an additional criteria for the choice of the proper adjuvant regimen in stage II/III colorectal cancer patients.

AB - Adjuvant treatment based on fluoropyrimidines (FL) improves the prognosis of stage II/III colorectal cancer (CRC). Validated predictive/prognostic biomarkers would spare therapy-related morbidity in patients with a good prognosis. We compared the impact of a set of 22 FL-related polymorphisms with the prognosis of two cohorts of CRC patients treated with adjuvant FL with or without OXA, including a total of 262 cases. 5,10-Methylentetrahydrofolate reductase (MTHFR) MTHFR-1298 A>C (rs1801131) polymorphism had a concordant effect: MTHFR-rs1801131-1298CC genotype carriers had a worse disease free survival (DFS) in both the cohorts. In the pooled population MTHFR-rs1801131-1298CC carriers had also a worse overall survival. We computed a clinical score related to DFS including MTHFR-rs1801131, tumor stage, sex and tumor location, where rs1801131 is the most detrimental factor (hazard ratio=5.3, 95% confidence interval=2.2-12.9; P-value=0.0006). MTHFR-rs1801131 is a prognostic factor that could be used as an additional criteria for the choice of the proper adjuvant regimen in stage II/III colorectal cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84929952032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929952032&partnerID=8YFLogxK

U2 - 10.1038/tpj.2014.64

DO - 10.1038/tpj.2014.64

M3 - Article

C2 - 25331073

AN - SCOPUS:84929952032

VL - 15

SP - 219

EP - 225

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 3

ER -